TCT-719
Effects of ranolazine in patients with acute coronary syndrome and stable angina according to whether they underwent percutaneous coronary intervention: Observations from the MERLIN-TIMI 36 Trial
Benjamin Scirica1, Sabina Murphy1, Ewa Karwatowska-Prokopczuk2, Gennanye Walker2, Luiz Belardinelli2, Ori Ben-Yehuda2, David Morrow3,1
1TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, 2Gilead Sciences, Forest City, CA

Background: Ranolazine is a late sodium current (late I Na) inhibitor with anti-ischemic effects that is indicated for the treatment of stable angina. Patients with a history stable angina who subsequently are admitted with ACS are at particularly high risk of recurrent ischemic events. We examined the 1-year incidence of recurrent CV events in patients with prior angina who had PCI within 30 days of the index event and whether ranolazine offered any incremental benefit compared to placebo.

Methods: 3565 patients in the MERLIN-TIMI 36 trial, which randomized patients with NSTE-ACS to ranolazine vs. placebo, reported a history of prior stable angina. The primary endpoint was the composite of CV death, MI, or recurrent ischemia (RI) defined as ischemia w/ ECG changes, leading to hospitalization, prompting revascularization, or worsening of stable angina prompting intensification of therapy.

Results: In this cohort of patients with prior angina presenting with NSTEACS, 914 patients underwent PCI within 30 days of randomization. Overall, patients who underwent PCI had lower rates of CV death, but higher rates of RI and MI than patients who did not undergo PCI. Ranolazine reduced the risk of RI regardless of whether patients did or did not have PCI (21.3 v. 29.8%, HR 0.71, p=0.011 and 14.7 v. 18.2%, HR 0.81, p=0.003). Ranolazine significantly reduced the risk of the primary endpoint, CV death, and RI leading to revascularization in patients who underwent PCI, whereas there was no benefit among patients who did not undergo PCI.

Conclusions: Regardless of whether patients underwent PCI or not for the treatment of ACS, ranolazine reduced the risk of recurrent ischemia during the 1 year following admission. In patients who did have PCI within 30 days of admission, rates of the primary endpoint and recurrent ischemia were lower in patients treated with ranolazine.

TCT-720
Triple Versus Dual Antiplatelet Therapy in Patients with Acute Myocardial Infarction and Renal Insufficiency:Results from Korea Acute Myocardial Infarction Registry
Sang Yup Lim1
1Korea University Ansan Hospital, Ansan, Korea, Republic of

Background: Whether triple antiplatelet therapy is superior or not to dual antiplatelet therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention in the era of renal insufficiency remains unclear.

Methods: As a part of the Korea Acute Myocardial Infarction Registry (KAMIR), 2288 AMI patients with renal insufficiency (GFR <60 ml/min) received either dual (aspirin plus clopidogrel; n=1587) or triple (aspirin plus clopidogrel plus cilostazol; n=701) antiplatelet therapy. Major adverse cardiac event (MACE) at 1- month and 1-year were compared between these two groups.

Results: Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. MACE rate at 1 month was significantly higher in the dual group than that of triple (16.3 % vs. 11.1%, p<0.05), which was mainly due to death rather than re-PCI (12.9 % vs. 9.1%, p<0.05). However, MACE rate at 1-year and MACE free survival day was not different between two groups.

Conclusions: In AMI patients with renal insufficiency, triple antiplatelet therapy exhibits a favorable in-hospital and short-term MACE event, but no difference in 1-year MACE free survival.

TCT-721
P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department
Rakesh Sharma1, Stephen Erickson2, Rohit Sharma3, Hanumath Reddy4, Donald Voelker5, Harvinder Dode6, Vibhuti Singh7, James Marsh8
1University of Arkansas for Medical Sciences, El Dorado, AR, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Medical Center of South Arkansas, El Dorado, AR, 4University of South Florida, Tampa, FL, 5University of Arkansas for Medical Sciences, Little Rock, AR

Background: Dual anti-platelet regimen has been shown to reduce major adverse cardiovascular events (MACE) after percutaneous coronary interventions (PCI). Variable response to clopidogrel can lead to pharmacodynamic failure, which may translate into clinical failure. We conducted a study to evaluate factors associated with hyporesponsiveness to clopidogrel with P2Y12 reactivity units by VerifyNow in previously stented patients presenting to the emergency department (ED) with chest pain while they were on dual anti-platelet regimen.

Methods: Hyporesponsiveness to clopidogrel was evaluated in a cohort of 531 consecutively enrolled patients with history of coronary artery stenting, presenting to ED with chest pain. Patients were labeled hyporesponders if they had P2Y12 Reactivity Units (PRU) ≥ 230. 221 patients (41.6%) had PRU≥230. A multivariable logistic regression model was used to determine the relationship between clopidogrel hyporesponsiveness and several potential risk factors, including gender, age, race, type I diabetes, type II diabetes, hypertension, smoking, chronic renal failure, and obesity.

Results: Out of this cohort of 531 patients, three predictors were statistically significant at p<0.05 (see table below): Type II diabetes (adjusted odds ratio, AOR 2.109, black race (AOR=2.165), and female gender (AOR=1.813). Age was a moderately significant predictor (p=0.058, AOR=1.167 per decade).

Conclusions: There is a high prevalence of clopidogrel hyporesponsiveness in patients presenting with chest pain. Out of multiple potential risk factors, type II diabetes and black race were the strongest predictors of clopidogrel hyporesponsiveness, followed by gender and age.

TCT-722
Platelet Function Testing Predicts Bleeding In Patients Exposed To Clopidogrel Undergoing Coronary Artery Bypass Grafting
Grant Reed1, Elaine Hoffman1, Amit Kumar2, Andrew Maree3, Dalton McLean4, Jacki Baros5, Gary Aranaki6, Prem Shekar7, Arvin Agnihotri7, Laura Williams8, Kenneth Rosenfeld1, Christopher Cannon9
1Brigham and Women’s Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Waterford Regional Hospital, Waterford City, Ireland, 4LeBauer Health Care, Greensboro, NC

Background: Clopidogrel use prior to coronary artery bypass grafting (CABG) is associated with increased bleeding. Whether a bedside platelet function test can predict bleeding in patients exposed to clopidogrel undergoing CABG is unknown. The aim of the current study was to determine a level of platelet reactivity as measured by the VerifyNow™ P2Y12 platelet function assay (Accumetrics, San Diego, CA) above which CABG can be undertaken in such patients without increased bleeding.

Antithrombin and Antiplatelet Agents

Hall D

Tuesday, October 23, 2012, 8:00 AM–10:00 AM

Abstract nos: 720-753

TCT-719
Ranolazine significantly reduced the risk of the primary endpoint, CV death, and RI defined as ischemia w/ ECG changes, leading to hospitalization, prompting revascularization, or worsening of stable angina prompting intensification of therapy.

Conclusions: Regardless of whether patients underwent PCI or not for the treatment of ACS, ranolazine reduced the risk of recurrent ischemia during the 1 year following admission. In patients who did have PCI within 30 days of admission, rates of the primary endpoint and recurrent ischemia were lower in patients treated with ranolazine.

TCT-720
Triple antiplatelet therapy is superior or not to dual antiplatelet therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention in the era of renal insufficiency remains unclear.

Methods: As a part of the Korea Acute Myocardial Infarction Registry (KAMIR), 2288 AMI patients with renal insufficiency (GFR <60 ml/min) received either dual (aspirin plus clopidogrel; n=1587) or triple (aspirin plus clopidogrel plus cilostazol; n=701) antiplatelet therapy. Major adverse cardiac event (MACE) at 1- month and 1-year were compared between these two groups.

Results: Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. MACE rate at 1 month was significantly higher in the dual group than that of triple (16.3 % vs. 11.1%, p<0.05), which was mainly due to death rather than re-PCI (12.9 % vs. 9.1%, p<0.05). However, MACE rate at 1-year and MACE free survival day was not different between two groups.

Conclusions: In AMI patients with renal insufficiency, triple antiplatelet therapy exhibits a favorable in-hospital and short-term MACE event, but no difference in 1-year MACE free survival.

TCT-721
Hyporesponsiveness to clopidogrel was evaluated in a cohort of 531 consecutively enrolled patients with history of coronary artery stenting, presenting to ED with chest pain. Patients were labeled hyporesponders if they had P2Y12 Reactivity Units (PRU) ≥ 230. 221 patients (41.6%) had PRU≥230. A multivariable logistic regression model was used to determine the relationship between clopidogrel hyporesponsiveness and several potential risk factors, including gender, age, race, type I diabetes, type II diabetes, hypertension, smoking, chronic renal failure, and obesity.

Results: Out of this cohort of 531 patients, three predictors were statistically significant at p<0.05 (see table below): Type II diabetes (adjusted odds ratio, AOR 2.109, black race (AOR=2.165), and female gender (AOR=1.813). Age was a moderately significant predictor (p=0.058, AOR=1.167 per decade).

Conclusions: There is a high prevalence of clopidogrel hyporesponsiveness in patients presenting with chest pain. Out of multiple potential risk factors, type II diabetes and black race were the strongest predictors of clopidogrel hyporesponsiveness, followed by gender and age.

TCT-722
Platelet Function Testing Predicts Bleeding In Patients Exposed To Clopidogrel Undergoing Coronary Artery Bypass Grafting

Conclusions: Regardless of whether patients underwent PCI or not for the treatment of ACS, ranolazine reduced the risk of recurrent ischemia during the 1 year following admission. In patients who did have PCI within 30 days of admission, rates of the primary endpoint and recurrent ischemia were lower in patients treated with ranolazine.
Conclusions: The VerifyNow™ P2Y12 platelet function assay can be used to predict perioperative bleeding in patients exposed to clopidogrel undergoing CABG. A threshold of ≥ 230 PRU is associated with less bleeding, and may assist clinicians in optimizing the timing of surgery.

TCT-723
Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-treatment Platelet Reactivity Analysis of the TRIPLET Trial

Jean Diosdado1, Dominick Angiolillo2, Jorge Sanchez3, Tracy Cardillo4, Joseph Jakubowski4, Joseph Jakubowski5, Mark Efron4, Fred Lipsett6, Harold Fisher2
1Hôpital du Sacré-Coeur de Montréal, Montréal, QC, 2University of Florida College of Medicine-Jacksonville, Jacksonville, United States, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Bad Homburg, Germany, 6Daiichi Sankyo Inc., Parsippany, NJ, 7Eli Lilly and Company, Toronto, Ontario

Background: High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for ischemic events in acute coronary syndrome (ACS) patients (pts). In TRIPLET, ACS pts undergoing percutaneous coronary intervention (PCI) were given a prasugrel (pras) loading dose (LD) with or without a prior clopidogrel (clop) LD. An analysis of HPR was included.

Methods: TRIPLET was a randomized, double-blind study in ACS-PCI pts on aspirin using VerifyNow P2Y12 assay to evaluate Pras with or without prior Clop in 3 arms: (1) placebo (PB) followed by Pras 60 mg-LD (2) Clop 60 mg-LD followed by Pras 30 mg-LD (3) Clop 600 mg-LD followed by Pras 60 mg-LD. Pts undergoing PCI received Pras 10 mg once daily (qd) for 2-4 days. HPR (P2Y12 Reaction Units [PRU] ≥240) were evaluated in the pharmacodynamic population within 24 hours following the PBO/Clop-LD, immediately prior to Pras LD and at 2, 6, 24, 72 hrs following Pras LDs. Results: HPR following Clop was 58.5% in the combined Clop LD arms. No substantial difference was noted when stratified by time between the Clop and Pras LDs (<6 hrs vs ≥6 hrs). At 6 hrs in the combined Pras LD arms, HPR was 7.1%, with 0% HPR by 72 hrs. Because a high number of HPR occurred in a single site, a statistical outlier analysis was performed. When outliers were excluded, HPR occurred in 1.9% at 6 hours and in 0% by 24 hrs.

Conclusions: In TRIPLET, pts with ACS intended for PCI showed a high prevalence of HPR after Clop 600-mg LD, even when measured after 6 hrs. When Pras LD was added, HPR decreased substantially by 6 hrs and was absent by 72 hrs.